中国冶金工业医学杂志

达格列净对2型糖尿病肾脏疾病患者血脂及肾功能的影响

作者：朱佳伟1 3 苏永峰2?

单位：1.内蒙古科技大学包头医学院研究生院内蒙古包头 014000 2.包头市中医蒙医医院 3.内蒙古包钢医院

分类号：R 587.2

出版年,卷(期):页码：2026,43(2):125-127

摘要：

摘要：目的本研究旨在分析探讨达格列净在2型糖尿病肾脏疾病中对血脂、肾功能的影响及其对肾脏的保护机制。方法选取2023年5月—2024年5月就诊于内蒙古包钢医院的2型糖尿病肾脏疾病患者50例为糖尿病肾脏疾病（diabetes kidney disease，DKD）组，选取同时期就诊的2型糖尿病（type 2 diabetes mellitus，T2DM）患者50例为对照组，两组均口服达格列净片治疗12周。记录两组的一般资料，检测两组治疗前及治疗12周后的肌酐（Cr）、尿素氮（BUN）、尿酸（UA）、甘油三酯（TG）、总胆固醇（TC）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、尿白蛋白/肌酐比值（UACR）指标。结果两组BMI、病程比较差异均有统计学意义（t＝－3.020，Z＝－3.225，均P＜0.05），两组年龄、性别、吸烟史、高血压史比较差异均无统计学意义（t＝－0.641，χ2＝0.404、0.667、3.241，均P＞0.05）。治疗前，DKD组Cr、BUN、TG、UACR均大于对照组，HDL-C小于对照组，组间比较差异均有统计学意义（t＝－3.330、－3.114、－2.143，Z＝－8.617、－2.158，均P＜0.05）；组间FPG、HbA1c、UA、TC、LDL-C比较差异均无统计学意义（t＝－1.058、－1.379、－1.291、－1.032、－1.533，均P＞0.05）。两组经达格列净治疗12周后，BMI、FPG、HbA1c、UA、TG、UACR均较治疗前下降，HDL-C均较治疗前升高，差异均有统计学意义（t＝3.131、5.092、2.161、2.471、5.267、3.345、3.226、2.526、3.324、4.233，Z＝－3.914、－5.681、－2.955、－3.167，均P＜0.05）；Cr、BUN、LDL-C均无明显变化，差异均无统计学意义（t＝1.065、1.850、－1.296、1.858、－0.918、1.728，均P＞0.05）。两组TC均下降，其中对照组的下降有统计学意义（t＝2.703，P＜0.05），DKD组的下降无统计学意义（t＝1.897，P＞0.05）。两组经达格列净治疗12周后的BMI、HbA1c、TG、TC、HDL-C、UACR指标比较差异均有统计学意义（t＝－2.731、－3.682、－2.291、－2.671，Z＝－2.900、－9.970，均P＜0.05）；而FPG、LDL-C指标比较差异均无统计学意义（t＝－1.975、0.348，均P＞0.05）。结论经达格列净治疗12周后，T2DM肾病患者的血糖、血脂、肾功能均有所改善。

Abstract：Objective This study aims to analyze and explore the effects of dapagliflozin on blood lipids and renal function in patients with type 2 diabetes kidney disease and its renal protective mechanism. Methods A total of 50 patients with type 2 diabetes kidney disease who were admitted to Baotou Hospital of Inner Mongolia from May 2023 to May 2024 were selected as the diabetes kidney disease（DKD） group, and 50 patients with type 2 diabetes mellitus (T2DM) who were treated during the same period were selected as the control group. Both groups were treated with oral dapagliflozin tablets for 12 weeks. General data of the two groups were recorded， and indicators including the creatinine （Cr）, urea （BUN）, uric acid （UA）, triglyceride （TG）, total cholesterol （TC）, high-density lipoprotein cholesterol （HDL-C）, low-density lipoprotein cholesterol （LDL-C）, and urine albumin/creatinine ratio （UACR） were measured before treatment and after 12 weeks of treatment. Results There were statistically significant differences in BMI and disease duration between the two groups （t＝－3.020, Z＝－3.225; both P＜0.05）; there were no statistically significant differences in age, gender, smoking history, or hypertension history between the two groups （t＝－0.641, χ2＝0.404, 0.667, 3.241; all P＞0.05）. Before treatment, Cr, BUN, TG, and UACR in the DKD group were higher than those in the control group, and HDL-C was lower than that in the control group, with statistically significant differences between the groups （t＝－3.330, －3.114, －2.143, Z＝－8.617, －2.158; all P＜0.05）; there were no statistically significant differences in FPG, HbA1c, UA, TC, and LDL-C between the groups （t＝－1.058, －1.379, －1.291, －1.032, －1.533; all P＞0.05）. After 12 weeks of treatment with dapagliflozin, BMI, FPG, HbA1c, UA, TG, and UACR in both groups decreased compared with those before treatment, and HDL-C increased compared with that before treatment, with statistically significant differences （t＝3.131, 5.092, 2.161, 2.471, 5.267, 3.345, 3.226, 2.526, 3.324, 4.233, Z=－3.914, －5.681, －2.955, －3.167; all P＜0.05）; Cr, BUN, and LDL-C showed no significant changes, with no statistically significant differences （t＝1.065, 1.850, －1.296, 1.858, －0.918, 1.728; all P＞0.05）. TC decreased in both groups, with a statistically significant decrease in the control group （t＝2.703, P＜0.05） and no statistically significant decrease in the DKD group （t＝1.897, P＞0.05）. After 12 weeks of treatment with dapagliflozin, there were statistically significant differences in BMI, HbA1c, TG, TC, HDL-C, and UACR between the two groups （t＝－2.731, －3.682, －2.291, －2.671, Z＝－2.900, －9.970; all P＜0.05）; there were no statistically significant differences in FPG or LDL-C between the groups （t＝－1.975, 0.348; both P＞0.05）.Conclusion After 12 weeks of treatment with dapagliflozin, blood glucose, blood lipids, and renal function in patients with T2DM and kidney disease are improved.

基金项目：

作者简介：

参考文献：

参考文献

［ 1 ］ Kaze AD，Zhuo M，Kim SC，et al. Association of SGLT2 inhibitors with cardiovascular，kidney，and safety outcomes among patients with diabetic kidney disease：a meta-analysis［J］. Cardiovascular Diabetology， 2022， 21（1）：47.

［ 2 ］ Tentolouris A，Vlachakis P，Tzeravini E，et al. SGLT2 Inhibitors：a review of their antidiabetic and cardioprotective effects［J］.International Journal of Environmental Research and Public Health，2019， 16（16）：2965.

［ 3 ］ Han YZ，Du BX，Zhu XY，et al. Lipid metabolism disorder in diabetic kidney disease［J］. Frontiers in Endocrinology，2024（15）：1336402.

［ 4 ］ Tang M，Yao S，Cao H，et al. Interrelation between the lipid accumulation product index and diabetic kidney disease in patients with type 2 diabetes mellitus［J］. Frontiers in Endocrinology，2023（14）：1224889.

［ 5 ］ Sawaf H，Thomas G，Taliercio JJ，et al. Therapeutic advances in diabetic nephropathy［J］. Journal of Clinical Medicine，2022，11（2）：378.

服务与反馈：

【文章下载】【加入收藏】